Stephanie Sutton

The world is rapidly losing its ability to treat malaria, HIV and tuberculosis, as well as more common diseases such as dysentery and respiratory infections because of drug resistance, according to a report from the Center for Global Development.

The world is rapidly losing its ability to treat malaria, HIV, and tuberculosis, as well as more common diseases such as dysentery and respiratory infections because of drug resistance, according to a report from the Center for Global Development (CGD).

The handling of the H1N1 pandemic by the World Health Organization (WHO), EU agencies and national governments led to a "waste of large sums of public money, and unjustified scares and fears about the health risks faced by the European public", according to a report released by the Council of Europe.

The handling of the H1N1 pandemic by the World Health Organization (WHO), EU agencies and national governments led to a "waste of large sums of public money, and unjustified scares and fears about the health risks faced by the European public", according to a report released by the Council of Europe.

A study conducted by the European Medicines Agency (EMA) has shown that statistical methods using the EMA?s EudraVigilance database of adverse drug reaction reports can be used to detect drug safety issues "significantly earlier" compared with routine pharmacovigilance.

A study conducted by the European Medicines Agency (EMA) has shown that statistical methods using EMA's EudraVigilance database of adverse drug reaction reports can be used to detect drug safety issues "significantly earlier" compared with routine pharmacovigilance.

Fifty percent of the marketing authorization applications for human medicines submitted to the European Medicines Agency (EMA) in 2009 were for generic and hybrid medicines — 60% higher than the agency?s forecast.

A collaboration involving GlaxoSmithKline and two British universities is looking to create faster acting medicines with a technology that prints APIs onto a tablet?s surface.

Fifty percent of the marketing authorization applications for human medicines submitted to the European Medicines Agency (EMA) in 2009 were for generic and hybrid medicines?60% higher than the agency's forecast.

More acquisitions are expected as the patent cliff pushes the pharma industry into a critical phase, with many executives believing that the industry will be unable to innovate sufficiently from within to replace blockbuster drugs.

Pfizer has begun implementing the first phase of its Plant Network Strategy, which will result in the loss of approximately 6000 jobs over the next several years.

More acquisitions are expected as the patent cliff pushes the pharma industry into a critical phase, with many executives believing that the industry will be unable to innovate sufficiently from within to replace blockbuster drugs.

The European Ombudsman has recommended that the European Medicines Agency (EMA) review its refusal to grant public access to reports on adverse drug reactions.

The European Ombudsman has recommended that the European Medicines Agency review its refusal to grant public access to reports on adverse drug reactions.

In response to stringent price cuts introduced in Spain, the European Generics Association (EGA) is urging the Spanish government to adopt mechanisms that will help increase the dispensing of generic medicines.

2016 will see Pfizer continue to cling to first place in the top ten pharma list, but Merck & Co. and Novartis will not be far behind.

The year 2016 will see Pfizer barely continue to cling to first place on the Top 10 pharma list, with Merck & Co. and Novartis not far behind.

Vetter has signed a preferred partnership with Sentry BioPharma Services whereby Vetter will fill early-stage, high-value biopharmaceuticals at its Chicago facility and Sentry will label, package and ship the clinical supplies from its site in Indianapolis.

A new automated factory in Boston (MA, USA) has been developed that uses non-genetically modified green plants to quickly produce large quantities of vaccines and therapeutics.

After completing the first phase of a project designed to increase the consistency and transparency of the EU regulatory process, the European Medicines Agency (EMA) has published a summary report that includes suggestions for improving the current processes for evaluating benefit?risk.

The European Medicines Agency published a summary report that includes suggestions for improving the current processes for evaluating benefit-risk.

AstraZeneca has finalized its agreement with US federal and state entities, under which it will pay $520 million to resolve allegations that it marketed the anti-psychotic drug Seroquel for off-label uses.

An evaluation conducted by Ernst & Young assessing the effectiveness and efficiency of the European Medicines Agency has largely praised the agency; however, a number of strategic and operational recommendations for further improvements have also been made.

Despite pharma's upcoming peak years of patent expiries and the threat of generic competition, growth during the next 5 years is expected to be strong with the global market for pharmaceuticals forecast to reach more than $1 trillion by 2014, according to IMS Health.

Orphan drugs may help pharma companies to reduce the impact of revenue loss caused by patent expiries of blockbuster drugs, according to market analysts Frost & Sullivan.

Regenerative medicine has been described as holding the "promise of cures" by speakers at the first annual Translational Regenerative Medicine Forum, which was held last week in the US.

Orphan drugs may help pharmaceutical companies reduce the effect of revenue loss caused by patent expirations of blockbuster drugs, according to Frost and Sullivan.

A report from Thomson Reuters claims the number of patent challenges in the US almost doubled between 2008 and 2009.

The European Generic Medicines Association (EGA) is calling for an urgent reform of the European patent system; in particular, the agency stresses that the quality of patent examinations and applications should be improved, and that examination and opposition proceedings should be accelerated.

The European Generic Medicines Association is calling for a reform of the European patent system.